과제정보
연구 과제 주관 기관 : Ministry of Health and Welfare
참고문헌
- Khanna D, Fitzgerald JD, Khanna PP, et al. 2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res (Hoboken) 2012;64:1431-1446. https://doi.org/10.1002/acr.21772
- Siu YP, Leung KT, Tong MK, Kwan TH. Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level. Am J Kidney Dis 2006;47:51-59. https://doi.org/10.1053/j.ajkd.2005.10.006
- Gaffo AL, Saag KG. Drug treatment of hyperuricemia to prevent cardiovascular outcomes: are we there yet? Am J Cardiovasc Drugs 2012;12:1-6. https://doi.org/10.2165/11594580-000000000-00000
- Lang PG Jr. Severe hypersensitivity reactions to allopurinol. South Med J 1979;72:1361-1368. https://doi.org/10.1097/00007611-197911000-00004
- Singer JZ, Wallace SL. The allopurinol hypersensitivity syndrome: unnecessary morbidity and mortality. Arthritis Rheum 1986;29:82-87. https://doi.org/10.1002/art.1780290111
- Marotti M. Severe cutaneous adverse reactions (SCAR) syndromes. Rev Assoc Med Bras 2012;58:276-278. https://doi.org/10.1016/S0104-4230(12)70193-8
- Halevy S, Ghislain PD, Mockenhaupt M, et al. Allopurinol is the most common cause of Stevens-Johnson syndrome and toxic epidermal necrolysis in Europe and Israel. J Am Acad Dermatol 2008;58:25-32. https://doi.org/10.1016/j.jaad.2007.08.036
- Mockenhaupt M, Viboud C, Dunant A, et al. Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs: the EuroSCAR-study. J Invest Dermatol 2008;128:35-44. https://doi.org/10.1038/sj.jid.5701033
- Baumann MA, Frick JC, Holoye PY. The tumor lysis syndrome. JAMA 1983;250:615. https://doi.org/10.1001/jama.1983.03340050027019
- Cohen LF, Balow JE, Magrath IT, Poplack DG, Ziegler JL. Acute tumor lysis syndrome: a review of 37 patients with Burkitt’s lymphoma. Am J Med 1980;68:486-491. https://doi.org/10.1016/0002-9343(80)90286-7
- Burghi G, Berrutti D, Manzanares W. Tumor lysis syn-drome in intensive therapy: diagnostic and therapeutic encare. Med Intensiva 2011;35:170-178. https://doi.org/10.1016/j.medin.2010.07.014
- Wilson FP, Berns JS. Onco-nephrology: tumor lysis syndrome. Clin J Am Soc Nephrol 2012;7:1730-1739. https://doi.org/10.2215/CJN.03150312
- Nicoll D, Lu CM, Pignone M, McPhee SJ. Pocket Guide to Diagnostic Tests. 6th ed. Stamford: McGraw-Hill, 2012.
- Yue TF, Gutman AB. Effect of allopurinol (4-hydroxypyrazolo-(3,4-d)pyrimidine) on serum and urinary uric acid in primary and secondary gout. Am J Med 1964;37:885-898. https://doi.org/10.1016/0002-9343(64)90131-7
- Edwards NL. The role of hyperuricemia and gout in kidney and cardiovascular disease. Cleve Clin J Med 2008;75 Suppl 5:S13-S16.
- Goncalves JP, Oliveira A, Severo M, Santos AC, Lopes C. Cross-sectional and longitudinal associations between serum uric acid and metabolic syndrome. Endocrine 2012;41:450-457. https://doi.org/10.1007/s12020-012-9629-8
- Johnson RJ, Kang DH, Feig D, et al. Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease? Hypertension 2003;41:1183-1190. https://doi.org/10.1161/01.HYP.0000069700.62727.C5
- Kantor GL. Toxic epidermal necrolysis, azotemia, and death after allopurinol therapy. JAMA 1970;212:478-479. https://doi.org/10.1001/jama.1970.03170160066019
- Ramasamy SN, Korb-Wells CS, Kannangara DR, et al. Allopurinol hypersensitivity: a systematic review of all published cases, 1950-2012. Drug Saf 2013;36:953-980. https://doi.org/10.1007/s40264-013-0084-0
- Hung SI, Chung WH, Liou LB, et al. HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc Natl Acad Sci U S A 2005;102:4134-4139. https://doi.org/10.1073/pnas.0409500102
- Tassaneeyakul W, Jantararoungtong T, Chen P, et al. Strong association between HLA-B*5801 and allopurinol- induced Stevens-Johnson syndrome and toxic epidermal necrolysis in a Thai population. Pharmacogenet Genomics 2009;19:704-709. https://doi.org/10.1097/FPC.0b013e328330a3b8
- Jung JW, Song WJ, Kim YS, et al. HLA-B58 can help the clinical decision on starting allopurinol in patients with chronic renal insufficiency. Nephrol Dial Transplant 2011;26:3567-3572. https://doi.org/10.1093/ndt/gfr060
- Somkrua R, Eickman EE, Saokaew S, Lohitnavy M, Chaiyakunapruk N. Association of HLA-B*5801 allele and allopurinol- induced Stevens Johnson syndrome and toxic epidermal necrolysis: a systematic review and meta-analysis. BMC Med Genet 2011;12:118. https://doi.org/10.1186/1471-2350-12-118
- Kaniwa N, Saito Y, Aihara M, et al. HLA-B locus in Japanese patients with anti-epileptics and allopurinol-related Stevens-Johnson syndrome and toxic epidermal necrolysis. Pharmacogenomics 2008;9:1617-1622. https://doi.org/10.2217/14622416.9.11.1617
- Gibson SE, Luo J, Sathanoori M, Liao J, Surti U, Swerdlow SH. Whole-genome single nucleotide polymorphism array analysis is complementary to classical cytogenetic analysis in the evaluation of lymphoid proliferations. Am J Clin Pathol 2014;141:247-255. https://doi.org/10.1309/AJCPRHGHT28DUWLA
- Kang HR, Jee YK, Kim YS, et al. Positive and negative associations of HLA class I alleles with allopurinol-induced SCARs in Koreans. Pharmacogenet Genomics 2011;21:303-307. https://doi.org/10.1097/FPC.0b013e32834282b8
- Rice KL, Lin X, Wolniak K, et al. Analysis of genomic aberrations and gene expression profiling identifies novel lesions and pathways in myeloproliferative neoplasms. Blood Cancer J 2011;1:e40. https://doi.org/10.1038/bcj.2011.39
- Cluzeau T, Moreilhon C, Mounier N, et al. Total genomic alteration as measured by SNP-array-based molecular karyotyping is predictive of overall survival in a cohort of MDS or AML patients treated with azacitidine. Blood Cancer J 2013;3:e155. https://doi.org/10.1038/bcj.2013.52
- McInnes GT, Lawson DH, Jick H. Acute adverse reactions attributed to allopurinol in hospitalised patients. Ann Rheum Dis 1981;40:245-249. https://doi.org/10.1136/ard.40.3.245
- Stamp LK, Taylor WJ, Jones PB, et al. Starting dose is a risk factor for allopurinol hypersensitivity syndrome: a proposed safe starting dose of allopurinol. Arthritis Rheum 2012;64:2529-2536. https://doi.org/10.1002/art.34488
- Crawford J, Dale DC, Lyman GH. Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management. Cancer 2004;100:228-237. https://doi.org/10.1002/cncr.11882
- Aubock J, Fritsch P. Asymptomatic hyperuricaemia and allopurinol induced toxic epidermal necrolysis. Br Med J (Clin Res Ed) 1985;290:1969-1970. https://doi.org/10.1136/bmj.290.6486.1969
- Kim SC, Newcomb C, Margolis D, Roy J, Hennessy S. Severe cutaneous reactions requiring hospitalization in allopurinol initiators: a population-based cohort study. Arthritis Care Res (Hoboken) 2013;65:578-584. https://doi.org/10.1002/acr.21817
- Calogiuri G, Nettis E, Di Leo E, Foti C, Ferrannini A, Butani L. Allopurinol hypersensitivity reactions: desensitization strategies and new therapeutic alternative molecules. Inflamm Allergy Drug Targets 2013;12:19-28. https://doi.org/10.2174/1871528111312010004
- Yu KH. Febuxostat: a novel non-purine selective inhibitor of xanthine oxidase for the treatment of hyperuricemia in gout. Recent Pat Inflamm Allergy Drug Discov 2007;1:69-75. https://doi.org/10.2174/187221307779815020
- Chohan S. Safety and efficacy of febuxostat treatment in subjects with gout and severe allopurinol adverse reactions. J Rheumatol 2011;38:1957-1959. https://doi.org/10.3899/jrheum.110092
- Feng X, Dong K, Pham D, Pence S, Inciardi J, Bhutada NS. Efficacy and cost of single-dose rasburicase in prevention and treatment of adult tumour lysis syndrome: a meta-analysis. J Clin Pharm Ther 2013;38:301-308. https://doi.org/10.1111/jcpt.12061
- Mockenhaupt M. The current understanding of Stevens-Johnson syndrome and toxic epidermal necrolysis. Expert Rev Clin Immunol 2011;7:803-813; quiz 814-815. https://doi.org/10.1586/eci.11.66
- Schneck J, Fagot JP, Sekula P, Sassolas B, Roujeau JC, Mockenhaupt M. Effects of treatments on the mortality of Stevens-Johnson syndrome and toxic epidermal necrolysis: a retrospective study on patients included in the prospective EuroSCAR Study. J Am Acad Dermatol 2008;58:33-40. https://doi.org/10.1016/j.jaad.2007.08.039
- Alejandria MM, Lansang MA, Dans LF, Mantaring JB 3rd. Intravenous immunoglobulin for treating sepsis, severe sepsis and septic shock. Cochrane Database Syst Rev 2013;9:CD001090.
피인용 문헌
- Allopurinol : Allopurinol hypersensitivity syndrome: 11 case reports vol.1563, pp.1, 2015, https://doi.org/10.1007/s40278-015-3952-9
- HLA-B * 58:01 for Allopurinol-Induced Cutaneous Adverse Drug Reactions: Implication for Clinical Interpretation in Thailand vol.7, pp.None, 2015, https://doi.org/10.3389/fphar.2016.00186
- Negative correlation between serum uric acid and kidney URAT1 mRNA expression caused by resveratrol in rats vol.61, pp.10, 2015, https://doi.org/10.1002/mnfr.201601030
- Update on the prevention and treatment of tumor lysis syndrome vol.3, pp.1, 2015, https://doi.org/10.1177/2399369319837212
- Drug Reaction with Eosinophilia and Systemic Symptoms (DReSS): How Far Have We Come? vol.20, pp.2, 2019, https://doi.org/10.1007/s40257-018-00416-4
- In silico design and synthesis of targeted rutin derivatives as xanthine oxidase inhibitors vol.13, pp.1, 2015, https://doi.org/10.1186/s13065-019-0585-8
- Diagnostic Test Criteria for HLA Genotyping to Prevent Drug Hypersensitivity Reactions: A Systematic Review of Actionable HLA Recommendations in CPIC and DPWG Guidelines vol.11, pp.None, 2020, https://doi.org/10.3389/fphar.2020.567048